Market Overview

Immunomedics Reports Subcutaneous Injections of Low-Dose Veltuzumab Produced High Rates of Response in Relapsed Immune


Immunomedics, Inc. (Nasdaq: IMMU), today announced that two doses of veltuzumab produced an overall objective response rate of 67%, including an 18% durable complete response rate, in 39 evaluable patients with immune thrombocytopenia. Responses occurred across all doses tested, including the lowest dose at 80 mg, regardless of the route of administration, history of splenectomy or prior use of rituximab.

Posted-In: News FDA


Related Articles (IMMU)

View Comments and Join the Discussion!

Partner Center